Safety and Efficacy of Damoctocog Alfa Pegol in Previously Treated Children Aged 7 to < 12 Years With Severe Haemophilia A in the Phase 3, Open Label Alfa‐ <scp>PROTECT</scp> Main Study
Safety and Efficacy of Damoctocog Alfa Pegol in Previously Treated Children Aged 7 to < 12 Years With Severe Haemophilia A in the Phase 3, Open Label Alfa‐ PROTECT Main Study
Monika Maas Enriquez, Mauro Dávoli, Maria Elisa Mancuso, Gregory C. Makris et al.
Journal
European Journal Of Haematology
Topics
Hemophilia Treatment and Research
article
Safety and Efficacy of Damoctocog Alfa Pegol in Previously Treated Children Aged 7 to < 12 Years With Severe Haemophilia A in the Phase 3, Open Label Alfa‐ PROTECT Main Study
Monika Maas Enriquez, Mauro Dávoli, Maria Elisa Mancuso, Gregory C. Makris, Claudia Tueckmantel, Kaan Kavaklı, Heidi Glosli, N. Samji, Shveta Gupta, Anthony K. C. Chan, Mario Guillermo Arbesú, Matteo Luciani, Luciana C. Oliveira, Margareth C. Ozelo
article en
Abstract
No abstract available for this paper.
Publication Tag
European Journal Of HaematologyVol. 116(4)
Institutions
University of Mendoza (AR), Oslo University Hospital (NO), Universidade de Ribeirão Preto (BR), Humanitas University (IT), Universidade Estadual de Campinas (UNICAMP) (BR), Arnold Palmer Hospital for Children (US), McMaster Children's Hospital (CA), Ege University (TR), National Hospital (IN), Bambino Gesù Children's Hospital (IT), Fundação Hemopa (BR), Instituto Cardiovascular de Rosario (AR), IRCCS Humanitas Research Hospital (IT), Bayer (United Kingdom) (GB), Bayer (Germany) (DE)